trial · primary record
Belzutifan
Malignant Neoplasm
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2034-01-02 |
| Primary endpoint | Number of Participants Who Experience One or More Adverse Events (AEs) |
| Registry ID | NCT07700758 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:12.438Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07700758
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Belzutifan · compound